69 related articles for article (PubMed ID: 21774727)
21. Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET.
Wullich B; Sattler HP; Fischer U; Meese E
Anticancer Res; 1994; 14(2A):577-9. PubMed ID: 8017863
[TBL] [Abstract][Full Text] [Related]
22. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick L; Wang XY; Eley G; James CD
Cancer Res; 2000 Mar; 60(5):1383-7. PubMed ID: 10728703
[TBL] [Abstract][Full Text] [Related]
23. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme.
Malden LT; Novak U; Kaye AH; Burgess AW
Cancer Res; 1988 May; 48(10):2711-4. PubMed ID: 2834047
[TBL] [Abstract][Full Text] [Related]
24. Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma.
Liu X; Yu H; Yang W; Zhou X; Lu H; Shi D
Cancer Genet Cytogenet; 2010 Mar; 197(2):152-7. PubMed ID: 20193848
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
26. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
Hegi ME; Rajakannu P; Weller M
Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
[TBL] [Abstract][Full Text] [Related]
28. Correlation between amplification of the gene for the epidermal growth factor receptor (EGFR), data from preoperative proton-MR-spectroscopy (1HMRS) and histomorphometric data of glioblastomas.
Nafe R; Glienke W; Hattingen E; Schlote W; Lanfermann H; Zanella F
Anal Quant Cytol Histol; 2007 Aug; 29(4):199-207. PubMed ID: 17879627
[TBL] [Abstract][Full Text] [Related]
29. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt EE; Ichimura K; Reifenberger G; Collins VP
Cancer Res; 1994 Dec; 54(24):6321-4. PubMed ID: 7987821
[TBL] [Abstract][Full Text] [Related]
30. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
[TBL] [Abstract][Full Text] [Related]
31. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma specimens with TP53 mutations do not show EGFRvIII amplification.
Stoczynska-Fidelus E; Witusik-Perkowska M; Banaszczyk M; Bienkowski M; Szybka M; Piaskowski S; Cybula M; Jaskolski D; Papierz W; Liberski PP; Rieske P
Cancer Genet; 2011 May; 204(5):282-3. PubMed ID: 21665183
[No Abstract] [Full Text] [Related]
33. Identification of variants in NFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients.
Kim LH; Shin HD; Park BL; Jung JH; Kim JY; Kim YJ; Lee HS
Hum Mutat; 2003 Jun; 21(6):652-3. PubMed ID: 14961554
[TBL] [Abstract][Full Text] [Related]
34. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
35. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
36. FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma.
Nagasaka T; Gunji M; Hosokai N; Hayashi K; Ikeda H; Ito M; Inao S
Brain Tumor Pathol; 2007; 24(1):1-5. PubMed ID: 18095137
[TBL] [Abstract][Full Text] [Related]
37. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer.
Liptay S; Weber CK; Ludwig L; Wagner M; Adler G; Schmid RM
Int J Cancer; 2003 Jul; 105(6):735-46. PubMed ID: 12767057
[TBL] [Abstract][Full Text] [Related]
38. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.
Lake A; Shield LA; Cordano P; Chui DT; Osborne J; Crae S; Wilson KS; Tosi S; Knight SJ; Gesk S; Siebert R; Hay RT; Jarrett RF
Int J Cancer; 2009 Sep; 125(6):1334-42. PubMed ID: 19507254
[TBL] [Abstract][Full Text] [Related]
39. Heterozygous N-terminal deletion of IkappaBalpha results in functional nuclear factor kappaB haploinsufficiency, ectodermal dysplasia, and immune deficiency.
McDonald DR; Mooster JL; Reddy M; Bawle E; Secord E; Geha RS
J Allergy Clin Immunol; 2007 Oct; 120(4):900-7. PubMed ID: 17931563
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Bredel M; Bredel C; Juric D; Duran GE; Yu RX; Harsh GR; Vogel H; Recht LD; Scheck AC; Sikic BI
J Clin Oncol; 2006 Jan; 24(2):274-87. PubMed ID: 16365179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
